Quest Diagnostics: OVA1™

"Clinical proof
The OVA1 test was validated using a blood sample from 269 women, 72 of whom had a pathology-determined malignancy. When pre-surgical assessment was combined with results from the OVA1 test, the following results were concluded:^[1]

• Sensitivity for malignancy increased by 20% from 72% to 92% In all women, and as high as 96%in postmenopausal women,
• Approximately 70% of the malignancies missed by pre-surgical assessment alone were identified by OVA1
• A high negative predictive value (NPV-93%) strengthened the prediction that cancer is absent
• NPV was similar in pre- and postmenopausal women."